Operating cash flow is often referred to as the lifeblood of a firm. The vaccine makers received cash up-front from the government for the stockpiled vaccines. Such cash would be reported to stakeholders (financial analysts, stockholders, lenders, etc.) in the operating cash flow section of the Statement of Cash Flows in the fiscal period of receipt. Given this, why would these pharmaceutical companies be so concerned about when the revenue related to this cash is recognized for income statement purposes? In your response, consider how recognized revenues are used by firm stakeholders.